Premier Alternatives

Loyal

Other Pharmaceuticals and Biotechnology · San Francisco, CA · Founded 2019 · Privately Held (backing)

Developer of veterinary drugs designed to improve dogs' health span and lifespan. Loyal is based in San Francisco, CA and was founded in 2019. It was valued at $430 million at its later-stage round in Feb 2025, the last priced event on record. It has raised $236 million across 1 recorded round; the latest was a $27.7 million Series A in Sep 2021.

PMV mark · valuation
$430.0M
Oct 2026
Priced at
its later-stage round
Feb 2025
Total raised
$236.5M
Last round
Early Stage VC (Series A)
Sep 2021

Loyal key facts

as of Oct 2026
  • Developer of veterinary drugs designed to improve dogs' health span and lifespan.
  • Loyal is valued at approximately $430.0M as of Oct 2026, set at its later-stage round, Feb 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $236.5M across 1 recorded rounds; the latest was Early Stage VC (Series A) ($27.7M) in Sep 2021.
  • Notable investors include Khosla Ventures, Gaingels, Metaplanet Holdings, BoxGroup, Pareto Holdings — 42 tracked in total.
  • 1 investment vehicle was formed to buy Loyal shares in the last 12 months, reporting $638K sold to 40 investors, per SEC Form D filings.
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$430.0M

Valued at $430.0M at its later-stage round, Feb 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Loyal with a free account
  • ·The complete investor list: 42 names
  • ·Watch Loyal: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Loyal funding rounds

1 rounds
Sep 2021Early Stage VC (Series A)$27.7M▮
Full funding history →

Vehicles formed to buy Loyal shares

secondary demand · SEC Form D filings

In the last 12 months, 1 investment vehicle were formed to buy Loyal shares, reporting $638K sold to 40 investors. Most recent filing Jan 2026.

The vehicle list — each sponsor, filing date, amount sold and investor count — is a Pro table. Unlock the 1 vehicle →

Membership and data by Private Market View

Companies with the most vehicle activity →

Loyal valuation

Loyal was valued at $430 million at its later-stage round in Feb 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Loyal raised?

Loyal has raised $236 million in total; 1 of its rounds is on record. The largest on record was a $27.7 million Series A in Sep 2021.

Institutional holders and vehicles

In the last 12 months, 1 investment vehicle was formed to buy Loyal shares, reporting $638,450 sold to 40 investors, per SEC Form D filings (most recent Jan 2026).

Loyal investors

42 investors are on record for Loyal, including Khosla Ventures, Gaingels, Metaplanet Holdings and BoxGroup. By type, the record holds 12 venture capital firms and 2 growth equity firms. The Series A in Sep 2021 drew 9 investors.

About Loyal

Developer of veterinary drugs designed to improve dogs' health span and lifespan. The company's drugs delay the onset of age-related diseases like cancer, heart disease, and metabolic diseases, enabling pet owners to help their dogs live healthier and longer lives.

Industry
Other Pharmaceuticals and Biotechnology
Sector
Consumer Products and Services (B2C)
HQ
San Francisco, CA, United States
Founded
2019
Employees
195
Website
loyal.com/
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.